Needle in a haystack: identifying drivers of malignant transformation in neurofibromas

Suganth Suppiah^{1

2}, Kenneth Aldape^{2

3}, Gelareh Zadeh^{2

4

5}

Affiliations

¹ Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
² MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
³ Laboratory of Pathology, Centre for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
⁴ Division of Neurosurgery, University Health Network, Toronto, Ontario, Canada.
⁵ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Comment

Suganth Suppiah et al. Neuro Oncol. 2019.

. 2019 Aug 5;21(8):961-962.

doi: 10.1093/neuonc/noz086.

Suganth Suppiah^{1

2}, Kenneth Aldape^{2

3}, Gelareh Zadeh^{2

4

5}

¹ Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
² MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
³ Laboratory of Pathology, Centre for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
⁴ Division of Neurosurgery, University Health Network, Toronto, Ontario, Canada.
⁵ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

No abstract available

Comment on

Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E, Miettinen MM, Fetsch P, Brems H, Chandrasekharappa SC, Jones K, Zhu B, Wei JS; National Intramural Sequencing Center (NISC) Comparative Sequencing Program; National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Cancer Genomics Research Laboratory; Mullikin JC, Wallace MR, Khan J, Legius E, Widemann BC, Stewart DR. Pemov A, et al. Neuro Oncol. 2019 Aug 5;21(8):981-992. doi: 10.1093/neuonc/noz028. Neuro Oncol. 2019. PMID: 30722027 Free PMC article.

1. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–314. - PMC - PubMed
1. Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017;2017:7429697. - PMC - PubMed
1. Pemov A, Hansen NF, Sindiri S, et al. . Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 2019;21(8):981–992. - PMC - PubMed
1. Lee W, Teckie S, Wiesner T, et al. . PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227–1232. - PMC - PubMed
1. Zhang M, Wang Y, Jones S, et al. . Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1170–1172. - PMC - PubMed